Wilson's Disease clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease

    open to eligible people ages 18 years and up

    The primary objectives of this study are to evaluate the safety of single IV doses of UX701 in patients with Wilson disease, to select the UX701 dose with the best benefit/risk profile based on the totality of safety and efficacy data and to evaluate the effect of UX701 on copper regulation.

    Los Angeles, California and other locations

Our lead scientists for Wilson's Disease research studies include .

Last updated: